Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer
This is a cooperative research project involving patients on the Thoracic Oncology Service
at Memorial Sloan-Kettering Cancer Center, and the laboratory of Dr. Peter Danenberg,
Professor of Biochemistry and Molecular Biology, University of Southern California / Norris
Comprehensive Cancer Center in Los Angeles, California. The primary objectives are to
measure the proportion of patients with advanced (stage III-IV) lung cancer with methylated
genes in their blood, and to determine if response to chemotherapy (complete or partial
radiologic response) in patients with advanced lung cancer renders methylated genes
undetectable in the blood. This research project will enroll approximately 80 patients per
year over 4 years to generate a sample size of approximately 320 patients.Blood will be
collected from participating patients at baseline, as close as possible to the date of their
baseline radiologic assessment. Three follow-up blood collections will be drawn, each within
7-10 days of each follow-up radiologic evaluation.
Observational Model: Case Control, Time Perspective: Prospective
To measure the proportion of patients with advanced (stage IIIB/IV) lung cancer with methylated genes in their blood and determine if response to chemotherapy (CR or PR radiologic response) renders methylated genes undetectable in blood.
Christopher Azzoli, M.D.
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|